HC Wainwright Issues Pessimistic Forecast for GPCR Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Investment analysts at HC Wainwright decreased their FY2025 earnings estimates for shares of Structure Therapeutics in a research note issued to investors on Thursday, August 7th. HC Wainwright analyst A. Ghosh now anticipates that the company will earn ($1.22) per share for the year, down from their prior forecast of ($1.12). HC Wainwright currently has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Structure Therapeutics' FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($2.20) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at ($2.41) EPS.

A number of other analysts have also recently commented on the stock. Guggenheim cut their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd. Citigroup assumed coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target for the company. Finally, JMP Securities cut their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average target price of $75.71.

Structure Therapeutics Stock Performance

Structure Therapeutics stock traded down $0.39 during mid-day trading on Monday, reaching $18.77. The company's stock had a trading volume of 256,625 shares, compared to its average volume of 876,652. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -17.94 and a beta of -1.89. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $45.37. The business's 50 day simple moving average is $19.58 and its 200 day simple moving average is $21.65.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08).

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently modified their holdings of GPCR. GF Fund Management CO. LTD. bought a new position in Structure Therapeutics during the fourth quarter worth about $34,000. National Bank of Canada FI increased its position in Structure Therapeutics by 1,448.2% during the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after acquiring an additional 2,766 shares during the period. Assetmark Inc. increased its position in Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock worth $60,000 after acquiring an additional 820 shares during the period. Virtus ETF Advisers LLC increased its position in Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after acquiring an additional 455 shares during the period. Finally, ANTIPODES PARTNERS Ltd increased its position in Structure Therapeutics by 310.7% during the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after acquiring an additional 3,213 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.